Journal of Thoracic Oncology
Scope & Guideline
Empowering Innovation in Thoracic Oncology
Introduction
Aims and Scopes
- Lung Cancer Research:
The journal covers a wide spectrum of lung cancer research, including molecular biology, genetics, treatment outcomes, and clinical trials for various lung cancer subtypes. - Mesothelioma Studies:
Research related to malignant pleural mesothelioma, including treatment protocols, clinical trials, and epidemiology, is a significant focus area. - Innovative Therapeutics:
The journal emphasizes studies on novel therapeutic approaches, including targeted therapies, immunotherapies, and combinations thereof, particularly in advanced stages of lung cancer. - Patient Outcomes and Quality of Life:
Research that investigates the impact of treatments on patient outcomes, including survival rates, quality of life, and health-related quality of life assessments. - Diagnostics and Biomarkers:
The journal publishes studies on the development and validation of diagnostic tools and biomarkers that aid in early detection and personalized treatment strategies for lung cancer. - Health Disparities and Epidemiology:
Exploration of health disparities in lung cancer diagnosis and treatment across different demographics and geographic locations. - Radiation Oncology:
Research focusing on the role of radiotherapy in lung cancer treatment, including techniques, dosimetry, and outcomes related to radiation therapy.
Trending and Emerging
- Precision Medicine and Genomic Targeting:
There is an increased focus on precision medicine, with studies exploring the genomic landscape of lung cancer and how specific mutations can guide targeted therapies. - Immunotherapy and Combination Therapies:
Research on immunotherapeutic approaches, particularly combinations of immunotherapy with chemotherapy or targeted therapies, is gaining momentum as a primary treatment strategy. - Real-World Evidence:
There is a growing trend towards publishing real-world evidence studies that assess treatment patterns, outcomes, and patient demographics outside of clinical trial settings. - Artificial Intelligence in Oncology:
The application of artificial intelligence and machine learning for predicting treatment outcomes, analyzing imaging data, and enhancing diagnostic accuracy is emerging as a significant theme. - Health Equity and Disparities:
Research addressing health disparities and the social determinants of health in lung cancer outcomes is increasingly prioritized, reflecting a broader commitment to equitable healthcare. - Patient-Reported Outcomes:
Studies examining patient-reported outcomes, quality of life, and the psychological impacts of lung cancer treatment are becoming more prevalent, emphasizing patient-centered care. - Liquid Biopsy and Minimal Residual Disease Monitoring:
The use of liquid biopsy techniques for early detection, monitoring treatment response, and assessing minimal residual disease is a rapidly emerging area of interest.
Declining or Waning
- Traditional Chemotherapy Studies:
Research focusing solely on traditional chemotherapy regimens has decreased, as there is a growing emphasis on targeted therapies and immunotherapy. - Basic Science without Clinical Correlation:
Studies that delve into basic science without clear clinical applications or implications are becoming less frequent, as the journal prioritizes translational research. - Single-Institution Studies:
There is a noticeable decline in single-institution studies, with more emphasis on multi-center trials and studies that provide broader data sets for analysis. - Non-Small Cell Lung Cancer (NSCLC) Generalities:
General reviews or studies on NSCLC without a specific focus on molecular characteristics, treatment responses, or innovative approaches are less common. - Epidemiological Studies without Intervention:
Epidemiological studies that do not propose specific interventions or actionable insights are waning, as the journal favors studies that lead to clinical advancements.
Similar Journals
BREAST CANCER RESEARCH AND TREATMENT
Uncovering Breakthroughs in Breast Cancer TreatmentBreast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.
JTO Clinical and Research Reports
Pioneering Excellence in Clinical and Research InsightsJTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.
ESMO Open
Empowering oncology through open access innovation.ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.
Interdisciplinary Cardiovascular and Thoracic Surgery
Uniting Specialties for Cutting-Edge Surgical InsightsInterdisciplinary Cardiovascular and Thoracic Surgery, published by Oxford University Press, stands as a leading platform in the field of cardiovascular and thoracic research. With an E-ISSN of 2753-670X, this journal aims to bridge the gap between various disciplines, encompassing advancements in surgical techniques, clinical practices, and innovative therapeutic approaches. It encourages contributions from researchers and practitioners alike, promoting collaboration and academic discourse among diverse specialties. With its commitment to open-access publishing, the journal ensures that cutting-edge research is readily available to a global audience, fostering knowledge sharing and enhancing patient care within the cardiovascular and thoracic communities. As the journal continues to evolve, it solidifies its importance as an essential resource for those dedicated to advancing the field.
Oncology Reviews
Unveiling Breakthroughs in Cancer CareOncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.
Clinical Medicine Insights-Oncology
Fostering collaboration in the fight against cancer.Clinical Medicine Insights-Oncology is a leading journal published by SAGE Publications Ltd, focusing on the interdisciplinary aspects of oncology. With an open access model since 2007, this journal fosters the dissemination of high-quality research and clinical insights that are crucial for advancing knowledge in cancer treatment and management. Based in New Zealand, it aims to bridge gaps in current oncology practices through the publication of innovative studies, case reports, and reviews. With a respectable ranking in Scopus at #264 out of 404 journals in the oncology category and belonging to the Q3 quartile, it positions itself as a valuable resource for oncologists, researchers, and students committed to enhancing patient outcomes. This journal strives to provide a platform for groundbreaking research that can impact clinical practice and inform policy within the field of oncology.
Breast Cancer
Exploring the latest in breast cancer science and care.Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.
Bladder Cancer
Empowering discoveries in bladder oncology.Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.
Current Problems in Cancer: Case Reports
Advancing oncology through shared case insights.Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Advancing the Frontiers of Cancer ResearchAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.